January 23, 2026

US Leaves WHO Over Pandemic, Governance

The announcement describes a shift toward direct engagement with countries and organizations outside the World Health Organization.

Conexiant

January 21, 2026

How Smoking Intensifies Periodontitis

Spatial transcriptomics links smoking to epithelial damage, inflammatory cell interactions, points to CXCL12 as potential therapeutic target.

Conexiant

January 20, 2026

IVF Babies and Allergy Risk: New Data

Cohort study of nearly 70,000 patients finds modest but statistically significant associations between assisted reproduction and asthma, allergic rhinitis, and atopic dermatitis

Conexiant

January 15, 2026

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

Conexiant

November 01, 2024

Are Antibiotics Needed for Pediatric Pneumonia?

Nearly one in five children diagnosed with pneumonia in outpatient settings did not receive antibiotics, according to a recent study in JAMA Network Open.

Conexiant

November 13, 2024

Is COPD Set to Affect 600M Globally?

GOLD 2025 highlights new pathways and advanced COPD therapies like ensifentrine and dupilumab to reduce exacerbations and address emerging COPD phenotypes.

Conexiant

April 29, 2024

Nasal Neomycin May Offer Virus Protection 

A study funded by the Melinda and Bill Gates Foundation demonstrates the potential of intranasal neomycin to elicit broad-spectrum antiviral immunity in the upper respiratory tract, providing significant protection against upper respiratory infections in animal models and showing promising results in a pilot human study.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

May 30, 2025

Mepolizumab Reduces COPD Flares in Eosinophilic Patients

A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.

Conexiant